HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health And Wellness Industry Regulatory Roundup

This article was originally published in The Rose Sheet

Executive Summary

Warning letter a year after recall; spiked supplement total climbs; FTC-USDA "organic" roundtable; and FTC ISO ICA for Herbalife.

You may also be interested in...



Califf Returns To US FDA Helm As Familiar Consumer Health Regulation Problems Continue

Announcement of Senate confirmation of Robert Califf as commissioner came shortly after FDA announced recalls of products labeled as supplements but spiked with ED drugs. Like those and others recently identified as adulterated, supplements with undisclosed drugs were being found during Califf’s first stint in 2016 and 2017.

FDA Reaps More Spiked Supplements From International Mail Shipments

FDA identifies 14 products in examinations of international mail shipments found to contain approved and banned drug ingredients indicated for weight loss, erectile dysfunction and depression.

Herbalife Claims No Harm, But FTC Hails 'Unprecedented' Settlement's Impact

In addition to imposing a $200m fine, the settlement requires the direct seller to determine compensation for its distributors based on actual retail sales, rather than on the number of additional distributors they bring into their networks, and to show at least 80% of its revenues are to end-users.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel